Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 2Other solid neoplasm 1

Conditions

Plasmacytoma 2Paraproteinemias 2Multiple Myeloma 2Leukemia, Plasma Cell 2Preleukemia 1Leukemia, Myeloid, Acute 1Advanced Solid Tumors 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × filanesib × Clear all
NCT00637052 2021-02-08

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

Pfizer

Phase 1/2 Completed
36 enrolled
Other hematologic neoplasm

Preleukemia, Leukemia, Myeloid, Acute

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT00462358 2020-09-28

A Study of ARRY-520 in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
41 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡